Longboard Pharmaceuticals, Inc. P/Revenue LTM
| Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|
| P/Revenue LTM | 0.0x | 0.0x | 0.0x |
Longboard Pharmaceuticals, Inc. (LBPH) P/Revenue LTM comparison analysis
General
LTM P/Revenue LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
LBPH key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.0) 0.0% | (0.0) 0.0% | (0.0) 0.0% |
| Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Research & Development Expenses (R&D) | 4.6 | 19.8 | 34.6 | 43.8 |
| Selling, General & Administrative Expenses (SG&A) | 9.8 | 8.1 | 10.2 | 13.0 |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
| Interest Income | 0.0 | 0.1 | 0.8 | 2.4 |
| Interest Expense | 0.0 | 0.0 | 0.8 | 0.0 |
| Pre-tax Income | (14.4) | (27.8) | (43.9) | (54.4) |
% effective tax rate | (0.0) 0.1% | (0.1) 0.2% | (0.9) 1.9% | 0.0 0.0% |
% margin | (14.4) 0.0% | (27.7) 0.0% | (43.1) 0.0% | (54.4) 0.0% |
| EPS | (0.82) | (1.62) | (2.51) | (2.39) |
| Diluted EPS | (0.82) | (1.62) | (2.51) | (2.39) |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Longboard Pharmaceuticals, Inc.'s P/Revenue LTM?
As of today, Microsoft Corp's last 12-month P/Revenue LTM is 155,830.1x, based on the financial report for Sep 27, 2024 (Q3’2024). The average annual P/Revenue LTM for Longboard Pharmaceuticals, Inc. have been 25,504.4x over the past three years, and 19,128.3x over the past five years.
2) Is Longboard Pharmaceuticals, Inc.'s P/Revenue LTM Good?
As of today, Longboard Pharmaceuticals, Inc.'s P/Revenue LTM is 155,830.1x, which is higher than industry median of 12.0x. It indicates that Longboard Pharmaceuticals, Inc.'s P/Revenue LTM is Bad.